The FDA's Drive to Spark Innovation

10 May 2018

Dr Nicola Davies

Due to the rising cost of drug development in an era when there is pressure to cut costs, pharma companies are losing any incentives to innovate, says Dr Nicola Davies in her monthly exclusive blog for The Pharma Letter. The US Food and Drug Administration Commissioner Scott Gottlieb is keen to address this problem and has sought funding from Congress to incentivize innovation in the pharmaceutical industry.1 So, what exactly are his ideas around spurring innovation within theindustry?We discuss six key areas on the Commissioner’s agenda.

Encouraging American-Grown MedTech Manufacturing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK